PEG-IFN is commonly associated with development of autoantibodies and with autoimmune disorders in 4% to 19% of patients, and SLE-like syndromes have been reported in 0.15% to 0.7% of patients on INF therapy [1], with the onset ranging from one month to seven years after INF administration. This evidence concerns the gene CBLIF and Autoimmunity.